Ichnos · industry survey
Can you advertise radiopharmaceutical cyclotron production and radiopharmacy distribution?
Yes — in 32 places we have confirmed, out of 485examined. Not on the major platforms: commercial cyclotrons manufacture ultrashort-lived diagnostic radioisotopes (such as Fluorine-18) that decay in hours and must be compounded in cleanroom hot cells under FDA prescription rules. Search engines reject non-retail prescription pharmaceutical manufacturing.
That is a fact about the platform’s category rules, not a finding about any business in it. The audience has not gone anywhere — it simply gathers somewhere the ad platforms do not sell access to. Each of the 32 says so in its own words, on its own page, and we quote the sentence — so the answer is checkable rather than asserted.
- Places found
- Publications, associations, forums and directories where this industry’s own language is actually spoken.
- Confirmed open
- These say in their own words that an outsider may take part. We quote the sentence, so you can judge it rather than take ours.
- You can simply buy
- Advertising, sponsored placement or event presence — a budget and a decision, not an application.
- Worth, per year
- Estimated value of the placement you could buy here. Banded from what each destination offers — not from rate cards we do not hold.
What these places let an outsider do
Almost none of it is guest posting. For an industry that cannot buy ads on the major platforms, an advertising page on a trade publication is not a lesser option — it is the channel.
Why the ordinary channels are closed
Most categories are locked out by one of these. Radiopharmaceutical cyclotron production and radiopharmacy distribution carries all three.
Refused outright by the ad platforms
The category is prohibited in policy, so there is no application, no certification and no appeal that opens it. Accounts that run it anyway are usually terminated rather than paused, and a terminated account takes its payment method, its pixel history and often the business manager with it.
Gated behind certification
Advertising is technically permitted but only after an approval process — often slow, often expensive, and frequently limited by state or by what may be said once approved. The gate is real rather than nominal: many businesses in the category never clear it, and those that do still cannot say the thing that would make the advertisement work.
Restricted by a regulator, not just a platform
A public body governs what may be claimed, to whom, and with what disclosure. This one does not go away by changing channel — the same rules apply to a trade publication, a conference talk and a mailing. What changes off-platform is that the channel will actually carry the message once it is compliant.
Where to start, and why in this order
Ordered by what you can act on soonest, not by what we found most of. A route that takes a rate card and a date beats one that takes a relationship, when the question is what to do on Monday.
- 1Buy advertising 11 places
11 of the 32 open destinations in radiopharmaceutical cyclotron production and radiopharmacy distribution sell placement outright, which makes this the fastest route in the category: there is nothing to negotiate and nobody to persuade, only a rate card and a date. 11 is enough to test two or three and keep the ones that return, but not enough to treat as a channel on its own.
- 2Send a press release 6 places
Free, and worth exactly as much as the news in it. 6 destinations publish announcements from radiopharmaceutical cyclotron production and radiopharmacy distribution. A category wire will run a genuine announcement — a licence, a location, a hire — and will ignore a rewritten product page.
- 3Place sponsored content 6 places
Slower and more expensive than a banner, and worth more: it carries the publication's context rather than sitting beside it. 6 destinations in radiopharmaceutical cyclotron production and radiopharmacy distribution will take it. Disclosure is mandatory and is not a drawback — an audience that knows what it is reading trusts the publication that told them, which in a category the platforms have already refused is worth more than the impression.
- 4Sponsor or exhibit 2 places
The most expensive route and often the highest intent, because the people in the room chose to be there. Radiopharmaceutical cyclotron production and radiopharmacy distribution has 2 destinations selling event presence. With only 2, the calendar is small enough that the good slots are spoken for months ahead — ask for next year's prospectus rather than this year's remainder.
- 5Join as a member 7 places
Slowest to pay off and hardest for a competitor to replicate. 7 bodies accept members from radiopharmaceutical cyclotron production and radiopharmacy distribution, and membership usually unlocks the newsletter, the directory and the event at member rates — so treat each one as the key to three routes rather than as one on its own. In a category the platforms refuse, standing is the asset that cannot be switched off by a policy change.
- 6Contribute an article 6 places
Requires something to say that somebody working in radiopharmaceutical cyclotron production and radiopharmacy distribution would not already know. 6 destinations accept contributed articles. Where it works it works well: a contributed piece carries a byline and a link and stays indexed for years, which is the one form of presence here that appreciates.
Start with these — free, no account
18 of the confirmed-open destinations for radiopharmaceutical cyclotron production and radiopharmacy distribution accept outside participation without charging for it. No budget, no ad account, no permission from a platform. Open any one and look for the way in.
- Canadian Nuclear Societycns-snc.caJoin as a member
“Become a Member Take advantage of many excellent opportunities to grow professionally by meeting and networking with colleagues in Canada and internationally Learn More”cns-snc.ca, read this year
- BELNUC Newsletterbelnuc.beJoin as a member
“The discounted tariff for BELNUC Members is: – € 104.00, paper and electronic subscription – € 94.00, electronic subscription only Do not forget to click this option during your annual online BELNUC membership application!”belnuc.be, read this year
- Health Physics Society (HPS)hps.orgJoin as a member
“Other activities include projects such as special membership surveys or reviews of the membership application/process.”hps.org, read this year
- American College of Radiology (ACR) Accreditationacr.orgJoin as a member
“Why should you become a member of the ACR? If you want to go far, go together.”acr.org, read this year
- NuclearHeritage.comnuclearheritage.comJoin as a member
“Join the society Donate your time and materials Participate in fundraising activities Spread word of the society Explore Artifacts & Reference Browse artifacts, reference material and video interviews.”nuclearheritage.com, read this year
- Applied Radiology Industry News Deskappliedradiology.comContribute an article
“As a general rule, Applied Radiology follows the manuscript submission guidelines and requirements set forth by the International Committee of Medical Journal Editors (ICMJE).”appliedradiology.com, read this year
- PRNobprnob.comContribute an article
“If you have questions about our editorial guidelines or need help preparing your press release, our team is here to assist you.”prnob.com, read this year
- Conference of Radiation Control Program Directors (CRCPD)crcpd.orgContribute an article
“Please review the following submission guidelines before submitting your abstract: Abstract submissions must be received by November 2, 2026 .”crcpd.org, read this year
- 24-7 Press Release Newswire24-7pressrelease.comSend news
“Send your press release using the industry’s most trusted distribution network.”24-7pressrelease.com, read this year
- LabXlabx.comJoin as a member
“Become a member and enjoy exclusive benefits Create an account now for exclusive benefits, personalized recommendations, and seamless order tracking.”labx.com, read this year
- openPR Healthcare and Industrial Engineering Channelsopenpr.comSend news
“How to Submit a Press Release on openPR.com The process of submitting a press release to our platform is designed to be straightforward and efficient, ensuring that your news is ready to make an impact in no time.”openpr.com, read this year
- U.S. Pharmacistuspharmacist.comContribute an article
“Please see our media kit here for the U.S. Pharmacist Editorial Calendar and a capabilities overview.”uspharmacist.com, read this year
- Pressatpressat.co.ukContribute an article
- Send2Press Newswiresend2press.comSend news
- Life Sciences Pennsylvanialifesciencespa.orgJoin as a member
- EIN Presswire (Sports & Recreation / Healthcare Channels)einpresswire.comSend news
- PR Undergroundprunderground.comSend news · Contribute an article
- BioSpacebiospace.comSend news
A further 19 destinations sell access outright — advertising, sponsored placement or event presence. Those need a budget and a decision rather than an application, and they come with the rate-card route and the sentence from each destination’s own policy page in the paid map.
Get the radiopharmaceutical cyclotron production and radiopharmacy distribution map
Every one of the 32 confirmed-open places, with what each lets you do and the sentence on their own site that says so. One industry, one payment, delivered as a file you keep. See a sample map first — it is a real one, with the identities withheld after the first three in each section.
A map is a dated reading, and policies move. Kept current is $997 a year — the same map plus quarterly re-verification of every route in it and the log of what opened, closed or changed terms in radiopharmaceutical cyclotron production and radiopharmacy distribution. Agencies running several restricted categories take every industry for $2,997 a year. Compare all four.
Questions people in this category actually ask
Answered plainly, including the one where the honest answer is “don’t”.
Why was my radiopharmaceutical cyclotron production and radiopharmacy distribution ad account banned or rejected?
Almost always for the category rather than for anything specific to your business. The major platforms apply their rules to radiopharmaceutical cyclotron production and radiopharmacy distribution as a class, so a licensed, compliant operator is refused on the same footing as one that is not. It is a fact about their category rules, not a finding about you — which is also why appealing rarely works: there is nothing about your individual account to reconsider.
Can I get around it with a second account or a different radiopharmaceutical cyclotron production and radiopharmacy distribution business name?
Do not. This is the advice most readily available elsewhere and it is the advice that ends businesses. Platforms link accounts by payment method, device, IP, business registration and staff logins; a second account discovered is usually a permanent termination of everything connected to it, rather than the suspension you started with. It is a particularly bad trade in radiopharmaceutical cyclotron production and radiopharmacy distribution, where 32 destinations already publish a way in and 19 of them will take your money today — you would be risking the business to avoid an afternoon's work. The route out of a category ban is a different channel, not a different login.
Where can radiopharmaceutical cyclotron production and radiopharmacy distribution advertise instead?
Where the industry already gathers. We have mapped 485 such places — trade publications, associations, professional forums and directories — and 32 of them publish a way in for outside businesses, read off their own pages and quoted. 19 of those sell advertising, sponsored placement or event presence outright, which means a budget and a decision rather than an application.
Is this just a list of radiopharmaceutical cyclotron production and radiopharmacy distribution websites?
No, and the difference is the whole product. A list of places your audience gathers is a reading list. What makes it a map is the permission column: for each place, whether it publishes a way in, what kind, and the sentence on their own site that says so. We read 485 destinations serving radiopharmaceutical cyclotron production and radiopharmacy distribution to find the 32 that say yes — and the 453 that say nothing either way are the reason a list is not enough. Anyone can assemble the list; the reading is the work.
Industries in the same position
Shut out the same way radiopharmaceutical cyclotron production and radiopharmacy distribution is — same kind of refusal, so the same shape of answer.
How this was assembled
Learn the language
The vocabulary this industry uses among itself — its regulators, licences, statutes and trade bodies. Say them correctly and you are inside the trade.
Find where it is spoken
The publications, associations and forums where that vocabulary actually appears. Not where an audience might be — where its language demonstrably is.
Check the way in
Whether each place accepts anything from outside, read from its own advertising or submissions page and quoted verbatim.